Gyros Establishes Dedicated Office in Japan
News Sep 23, 2016
Gyros Protein Technologies AB has announced that it has established a dedicated office in Tokyo, Japan and has established Gyros Japan KK. The dedicated Japan team provides sales, applications and service support in Japan for the Company’s Gyros’ immunoassay business.
Gyros Japan KK replaces support previously provided under the distribution agreement in Japan with GE Healthcare for Gyros Protein Technologies’ nanoliter-scale immunoassay platform business (Gyrolab xP workstation, Gyrolab xPlore, related reagents, consumables and service).
GE Healthcare will continue providing support for sales, technical support and maintenance service until the end of December 2016. Gyros Japan KK will take over full responsibility for the region from January 2017, ensuring a smooth transition for customers.
Peter Luk, Vice President Asia-Pacific, Gyros Protein Technologies, said: “We are delighted to
announce the opening of the Japan office, and would like to thank GE Healthcare for their continued support during this transition period. This marks an important development for Gyros Protein Technologies and demonstrates the company’s commitment to the Asia-Pacific region, which has seen significant growth in the biotherapeutic discovery, development and manufacturing markets in recent years.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE